Meeting
2021 ASCO Annual Meeting
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.
Authors
Rebecca Forman
Yale New Haven Hospital, New Haven, CT
Rebecca Forman , Aarti K. Bhatia , Barbara Burtness
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6042)
DOI
10.1200/JCO.2021.39.15_suppl.6042
Abstract #
6042
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Evaluation of the effectiveness of a new medical device containing verbascoside, polyvinylpyrrolidone, and hyaluronic acid in prevention and treatment of mucositis in patients with cancer.
First Author: Olga Nigro
Poster
2018 ASCO Annual Meeting
Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
First Author: Signe Friesland
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli